SillaJen is a privately-held biotechnology company focused on engineering and developing best-in-class oncolytic virus immunotherapeutics. A global leader in oncolytic immunotherapeutics Targeting, Attacking and Eradicating Cancers
Employees: 11-50
Total raised: $12M
Founded date: 2006
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.03.2016 | - | $12M | Medivate P... |
Mentions in press and media 6
| Date | Title | Description |
| 22.04.2024 | OSR Holdings and SillaJen have entered into a Memorandum of Understanding to collaboratively pursue the development of innovative therapeutics and enter the U.S. market | SEOUL, South Korea, April 22, 2024 /PRNewswire/ -- OSR Holdings, a global healthcare holding company, announced that it has signed a memorandum of understanding (MOU) with SillaJen, a Kosdaq-listed biotech firm with a pipeline of immuno-onc... |
| 19.12.2022 | Basilea announces transition milestone for oncology asset BAL0891, triggering milestone payment of USD 4 million by SillaJen | - |
| 19.12.2022 | Basilea announces transition milestone for oncology asset BAL0891, triggering milestone payment of USD 4 million by SillaJen | /EIN News/ -- Basel/Allschwil, Switzerland, December 19, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, annou... |
| 31.05.2021 | SILLAJEN, INC. SillaJen, Inc. announced that it expects to receive KRW 60 billion in funding from M2N Co.,Ltd | SillaJen, Inc. (KOSDAQ:A215600) announced a private placement of 18,750,000 shares at an issue price of KRW 3,200 per share for gross proceeds of KRW 60,000,000,000 on May 31, 2021. The transaction will involve participation from returning ... |
| 22.03.2016 | S Korean biotech firm Sillajen raises $12m from Medivate Partners | Premium Sillajen, a South Korea-based oncolytic immunotherapeutic startup, has raised $12 million funding from Medivate Partners, a private equity and venture capital firm investing in Asia and North America biotech and healthcare industry.... |
| 21.03.2016 | Sillajen Raises $12M in Funding | Sillajen, a Seoul, South Korea-based global oncolytic immunotherapeutic company, raised $12m in funding. Medivate Partners made the investment. In conjunction with the funding, Mr. Paul Kim, CEO & Managing Partner of Medivate Partners, ... |